Zymeworks (ZYME) Cash from Financing Activities (2021 - 2026)
Zymeworks recorded quarterly Cash from Financing Activities of $178.8 million in Q1 2026, up 1053.93% quarter-over-quarter from -$18.7 million in Q4 2025, and up 13485.56% year-over-year from N/an in Q1 2025.
Zymeworks' Cash from Financing Activities history runs 6 years deep, the most recent figure standing at $178.8 million for Q1 2026.
- In Q1 2026, Cash from Financing Activities rose 13485.56% year-over-year to $178.8 million; the TTM figure through Mar 2026 stood at $158.9 million (up 847.78% YoY), while the FY2025 annual figure was -$18.6 million, up 9.19% from the prior year.
- Cash from Financing Activities came in at $178.8 million for Q1 2026 at Zymeworks, up from -$18.7 million in the prior quarter.
- In the past five years, Cash from Financing Activities ranged from a high of $178.8 million in Q1 2026 to a low of -$18.7 million in Q4 2025.
- A 5-year average of $19.4 million and a median of $1.3 million in 2025 frame the typical range for Cash from Financing Activities.
- Across the five-year window, Cash from Financing Activities surged 13530.24% in 2023 and sank 889.87% in 2024, its largest moves.
- Zymeworks' Cash from Financing Activities stood at -$377000.0 in 2022, then soared by 13530.24% to $50.6 million in 2023, then plunged by 117.07% to -$8.6 million in 2024, then slumped by 116.87% to -$18.7 million in 2025, then jumped by 1053.93% to $178.8 million in 2026.
- According to Business Quant data, Cash from Financing Activities over the past three periods registered $178.8 million, -$18.7 million, and -$2.5 million for Q1 2026, Q4 2025, and Q3 2025 respectively.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Financing Activities (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - | 7.00 Mn |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - | - |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn | -600,000.00 |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - | - |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - | 53,000.00 |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn | -538.80 Mn |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - | - |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn | -802.20 Mn |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn | 15.71 Mn |
| 10 | Zymeworks | 1.84 Bn | 1.47 Bn | - | 178.79 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 178.79 Mn |
| Mar 31, 2026 | 178.79 Mn |
| Dec 31, 2025 | -18.74 Mn |
| Dec 31, 2025 | -18.74 Mn |
| Sep 30, 2025 | -2.45 Mn |
| Sep 30, 2025 | -2.45 Mn |
| Jun 30, 2025 | 1.32 Mn |
| Jun 30, 2025 | 1.32 Mn |
| Mar 31, 2025 | 1.32 Mn |
| Mar 31, 2025 | 1.32 Mn |
| Dec 31, 2024 | -8.64 Mn |
| Dec 31, 2024 | -8.64 Mn |
| Sep 30, 2024 | -14.98 Mn |
| Sep 30, 2024 | -14.98 Mn |
| Jun 30, 2024 | 1.05 Mn |
| Jun 30, 2024 | 1.05 Mn |
| Mar 31, 2024 | 2.13 Mn |
| Mar 31, 2024 | 2.13 Mn |
| Dec 31, 2023 | 50.63 Mn |
| Dec 31, 2023 | 50.63 Mn |
| Sep 30, 2023 | 1.90 Mn |
| Sep 30, 2023 | 1.90 Mn |
| Jun 30, 2023 | 27.60 Mn |
| Jun 30, 2023 | 27.60 Mn |
| Mar 31, 2023 | 1.74 Mn |
| Mar 31, 2023 | 1.74 Mn |
| Dec 31, 2022 | -377,000.00 |
| Dec 31, 2022 | -377,000.00 |
| Sep 30, 2022 | 628,000.00 |
| Sep 30, 2022 | 628,000.00 |
| Jun 30, 2022 | -279,000.00 |
| Jun 30, 2022 | -279,000.00 |
| Mar 31, 2022 | 108.61 Mn |
| Mar 31, 2022 | 108.61 Mn |
| Dec 31, 2021 | 689,000.00 |
| Dec 31, 2021 | 689,000.00 |